The window between brain damage and recovery after stroke may be far more dynamic than medicine has treated it. For millions of stroke survivors facing permanent disability despite technically successful clot removal, the bottleneck increasingly appears to lie in the inflammatory cascade that unfolds afterward — and whether interventions are timed to work with, rather than against, that cascade. This review synthesizes emerging evidence that challenges how the field has conceptualized post-stroke inflammation for decades.
Rather than framing neuroinflammation as uniformly harmful, this comprehensive review argues it operates as a temporally evolving and spatially heterogeneous continuum across four distinct phases: hyperacute, acute, subacute, and chronic. Microglia and astrocytes do not simply polarize into neat pro- or anti-inflammatory states — transcriptomic and spatial profiling data now reveal these cells cycle through multiple transitional states that can simultaneously drive tissue damage and support repair processes such as angiogenesis, debris clearance, and synaptic remodeling. The authors introduce the concept of an "immune window" — a phase-specific interval during which immunomodulatory intervention can amplify neuroplasticity without inadvertently suppressing reparative signaling, which prior broad-spectrum anti-inflammatory trials may have done.
This framework represents a meaningful conceptual advance over prior stroke immunology models. The failure of anti-inflammatory drugs in stroke trials has been a persistent puzzle; this review's precision-based interpretation — that timing, cellular heterogeneity, and individual factors like aging and comorbidities determine whether immune modulation helps or harms — offers a credible mechanistic explanation. It also aligns with broader trends in precision medicine. Key limitations are inherent to review-level evidence: the immune window concept, while compelling, awaits prospective validation in human trials. Most transcriptomic data remain preclinical. Still, for researchers and clinicians, this synthesis is more than incremental — it provides a tractable framework for designing next-generation stroke recovery trials where the question is not just whether to modulate inflammation, but precisely when and in whom.